Schonfeld Strategic Advisors LLC Increases Stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Schonfeld Strategic Advisors LLC increased its position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 343.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 42,614 shares of the company's stock after purchasing an additional 33,007 shares during the quarter. Schonfeld Strategic Advisors LLC owned 0.09% of Amphastar Pharmaceuticals worth $1,582,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the company. Smartleaf Asset Management LLC lifted its stake in Amphastar Pharmaceuticals by 222.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 715 shares of the company's stock valued at $26,000 after acquiring an additional 493 shares during the period. Parkside Financial Bank & Trust raised its holdings in shares of Amphastar Pharmaceuticals by 806.5% during the fourth quarter. Parkside Financial Bank & Trust now owns 979 shares of the company's stock worth $36,000 after purchasing an additional 871 shares during the last quarter. Tower Research Capital LLC TRC lifted its position in Amphastar Pharmaceuticals by 43.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,145 shares of the company's stock valued at $43,000 after purchasing an additional 348 shares during the period. Huntington National Bank boosted its holdings in Amphastar Pharmaceuticals by 36.9% in the fourth quarter. Huntington National Bank now owns 1,340 shares of the company's stock valued at $50,000 after purchasing an additional 361 shares during the last quarter. Finally, TD Private Client Wealth LLC grew its position in Amphastar Pharmaceuticals by 22.7% during the 4th quarter. TD Private Client Wealth LLC now owns 2,099 shares of the company's stock worth $78,000 after purchasing an additional 388 shares during the period. Hedge funds and other institutional investors own 65.09% of the company's stock.

Amphastar Pharmaceuticals Price Performance

Shares of Amphastar Pharmaceuticals stock traded down $0.54 on Friday, hitting $24.11. The company's stock had a trading volume of 790,220 shares, compared to its average volume of 475,974. The company has a market capitalization of $1.15 billion, a price-to-earnings ratio of 8.04, a price-to-earnings-growth ratio of 2.19 and a beta of 0.78. Amphastar Pharmaceuticals, Inc. has a 1 year low of $22.64 and a 1 year high of $53.96. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.61 and a current ratio of 3.43. The firm has a fifty day moving average price of $25.83 and a 200-day moving average price of $34.87.

Insider Activity

In other news, CFO William J. Peters sold 4,231 shares of Amphastar Pharmaceuticals stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $27.54, for a total value of $116,521.74. Following the sale, the chief financial officer now owns 97,363 shares in the company, valued at $2,681,377.02. This trade represents a 4.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders sold 5,231 shares of company stock worth $142,752 over the last three months. 27.50% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several equities analysts have recently issued reports on AMPH shares. Piper Sandler decreased their price objective on Amphastar Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating for the company in a report on Friday, March 21st. Needham & Company LLC restated a "hold" rating on shares of Amphastar Pharmaceuticals in a research report on Thursday, April 10th. Finally, Wells Fargo & Company cut their target price on shares of Amphastar Pharmaceuticals from $40.00 to $35.00 and set an "overweight" rating for the company in a report on Thursday.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.